Development and Investigation of Assays For Cardiovascular Risk Assessment

在过去的一年中，我们完成了几项与心血管生物标志物相关的研究，并发表了研究结果（见下文）。我们专注于在DLM中使用核磁共振设备来执行脂蛋白颗粒数量和大小的详细评估，这导致了几篇关于心血管风险标志物的出版物，主要是与NIH内部研究人员合作。就正在进行的工作而言，我们目前正在与NMR制造商进行CRADA，以改进用于测量脂蛋白的算法，该算法即将完成。通过新的算法，我们开发了一种识别iii型高脂血症的新技术，这种疾病现在经常被误诊。这是一种相对常见的脂质紊乱，影响了1-2%的人口，认识到这些患者很重要，因为他们不仅应该用他汀类药物治疗，还应该用降低甘油三酯的降脂药物治疗。

In the past year, we have completed several studies related to cardiovascular biomarkers and have published the findings (see below). We have focused on the use of the NMR device in DLM for performing a detailed assessment of lipoprotein particle number and size, which has led to several publications on cardiovascular risk markers mostly in collaboration with NIH intramural investigators. In terms of work in progress, we are currently working under a CRADA with the NMR manufacturer for improving the algorithm for measuring lipoproteins, which is close to completion. With the new algorithm, we have developed a novel technique for identifying Type-III hyperlipidemia, which is now commonly misdiagnosed. It is relatively common lipid disorder affecting as much as 1-2% of the population and it is important to recognize these patients because they should be treated with not only statins but with lipid lowering medications that lowers triglycerides.